Navigation Links
Shareholder Alert: Pomerantz Law Firm has filed a Class Action Against Biolase, Inc. and Certain Officers - BIOL

NEW YORK, Aug. 26, 2013 /PRNewswire/ -- Pomerantz Grossman Hufford Dahlstrom & Gross LLP has filed a class action lawsuit against Biolase, Inc.  ("Biolase" or the "Company") (NASDAQ: BIOL) and certain of its officers.  The class action, filed in United States District Court, Central District of California, and docketed under SACV 13-1317-DMG, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Biolase between November 5, 2012 and August 7, 2013 both dates inclusive (the "Class Period"). This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

If you are a shareholder who purchased Biolase securities during the Class Period, you have until October 22, 2013 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at   To discuss this action, contact Robert S. Willoughby at or 888.476.6529 (or 888.4-POMLAW), toll free, x237. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.

Biolase is a biomedical company that develops, manufactures, and markets lasers in dentistry and medicine and also markets and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intra-oral scanners.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business and operations. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company was facing near term solvency issues; (ii) the Company faced severe liquidity problems; (iii) the Company's sales were not as strong as reported; and (iv) as a result of the foregoing, the Company's financial statements were false and misleading at all relevant times.

On August 9, 2013, the Company announced in its quarterly report for the period ending June 30, 2013, that Biolase was in breach if its financial covenants related to its lines of credit.  On this news, shares of Biolase declined $1.61 per share, more than 47%, to close at 1.81 per share on August 13, 2013.

Then on August 14, 2013, an analyst report was published on which criticized the Company for misleading investors regarding the extent of its solvency problems as well as providing the market with false guidance regarding the Company's sales and the state of adoption of the Company's products by practitioners.  On this news, shares of Biolase declined $0.61 per share, more than 33%, to close at 1.20 per share on August 14, 2013.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and San Diego, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See

Robert S. Willoughby
Pomerantz Grossman Hufford Dahlstrom & Gross LLP

SOURCE Pomerantz Grossman Hufford Dahlstrom & Gross LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Acquisition of Onyx Pharmaceuticals, Inc. by Amgen Inc. May Not Be in the Best Interests of Onyx Pharmaceuticals, Inc. Shareholders
2. Concord Medical Announces Acquisition of Its Shares by CEO and COO from Other Shareholders
3. OPTIMER PHARMACEUTICALS SHAREHOLDER ALERT: Levi & Korsinsky Investigates Possible Breaches of Fiduciary Duty by Board of Optimer Pharmaceuticals, Inc. in Connection with Sale of Company to Cubist Pharmaceuticals, Inc.
4. FDA Approvals, Dividends, New Technologies, and Solid Margins Increase Shareholder Value - Research Report on Abbott, Baxter, CareFusion, Haemonetics, and CR Bard
5. Teamsters Protest McKessons Worker Abuse And Executive Pay At Shareholder Meeting
6. Alliquas CEO Issues Midyear Corporate Update for Shareholders
7. Sinovac Schedules 2013 Annual Meeting of Shareholders
8. Millenia Hope, Inc. Updates to Shareholders
9. Royalty Pharma Urges Elan Shareholders to Vote AGAINST ALL FOUR Elan Resolutions Today
10. CVBT Shareholders Vote for Change
11. Cytos Invites to the Annual Shareholders Meeting 2013
Post Your Comments:
(Date:11/26/2015)... November 26, 2015 ... adds "Global Repaglinide Industry ... Report on China Repaglinide Market, 2010-2019" ... data and information to its online ... . --> ...
(Date:11/26/2015)... 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in the ... Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new 247-page ... therapeutic drug monitoring market, including emerging tests, technologies, ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the European Cell Surface Marker Testing ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology:
(Date:11/28/2015)... (PRWEB) , ... November 28, 2015 , ... Safe storage ... creativity of two inventors, one from Lakewood, New Jersey and the other from Bradley ... the patent-pending PROTECTOR to save the expense of having to replace NuvaRings more often ...
(Date:11/28/2015)... ... ... a.m. EST until 11:59 p.m. EST, customers will be racing the clock ... $80 or more to free gifts with purchases, there will be a new sale available ... for skin care and cosmetic needs, customers will save on already discounted prices. , Top ...
(Date:11/27/2015)... ... ... There is only one major question facing all law firms in the ... has not been an easy question to answer. Especially when the senior partners and ... don’t share the same discipline around working long hours. , In addition to ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... University of Toronto and the University of British Columbia suggested that laws requiring bicyclists ... The article explains that part of the reason for the controversial conclusion is that, ...
(Date:11/27/2015)... ... November 27, 2015 , ... The rapid speed at which ... age, more care is needed, especially with Alzheimer’s, dementia and other cognitive conditions ... overworked. The forgotten part of this equation: 80 percent of medical care occurs ...
Breaking Medicine News(10 mins):